

澳大利亚生物技术协会 澳大利亚医疗技术公司名录

NeuralDiagnostics

公司介绍

公司名称: Neural Diagnostics Pty Ltd

主要联系人姓名: Dr. Roger Edwards

主要联系人职务: 首席执行官

公司网址: www.neuraldiagnostics.com

公司地址: Suit 16, 537 Malvern Road, Toorak VIC 3142

公司未上市

公司简介

Neural Diagnostics 股份有限公司(ND) 运营于年产值数十亿美元的全球神经技术市场, 为需花费数兆的精神与神经疾病提供服务。

Neural Diagnostics 股份有限公司(ND) 成立于 2005 年, 专注开发 EVestG™系统。由于脑波(神经反应)能够间接反映出大脑深层功能和脑干结构, 因此 EVestG™系统能通过脑波和 EVestG™软件的分析, 灵敏测量神经功能并提供大脑功能性的信息。此新技术致力于在医疗保健领域提供客观、快捷、低成本的检测和多种中枢神经系统疾病的区分和监测治疗。

自从赢得澳大利亚广播公司(ABC)“新发明者”节目 2010 年度最佳发明奖后, ND 公司在澳大利亚维多利亚州 Alfred 医院的 Monash Alfred 精神病研究所(MAPrc)、加拿大 Riverview 健康中心、加拿大温尼伯市 Manitoba 大学内对超过 400 名患者(阳性对照)进行评估并成功地与技术平台取得了概念验证。该研究项目得到了来自澳大利亚商业化计划(Commercialisation Australia)的 50 万澳币拨款。该项研究成果已发表于经同行评审的国际期刊。

目前, ND 公司准备对现有技术进行深度开发, 使其可以尽早、及时、快速地诊断复杂的中枢神经类疾病。这将有助于精神病科医师对患者实施正确用药和有效的心理辅导, 从而获得更经济的治疗效果。

ND 公司已成功地为 EVestG™申请了专利, 同时还对早期的原型机进行了临床测试, 发表了学术文献。现在 ND 已经准备好进一步开发该技术, 使其能帮助中枢神经类疾病的患者获得更好的诊断。

ND 有限公司的产品有潜力成为一款快速客观诊断脑功能的革命性产品。

关键技术或领先技术

有四分之一的人会患有严重的脑部疾病，如自闭症谱系障碍、阿尔茨海默氏症、帕金森、脑外伤和损伤、抑郁症、躁郁症或精神分裂症。不同于其他外伤，至今为止，人类仍没找到一种低成本、非侵入性、方便并客观的方法来测量脑功能。这将有助于快速准确地诊断由于情绪变化和行为举止引发的脑部和神经系统类疾病。对精神类疾病的诊断有可能需要花费长达 12 年的时间。而对患有狂躁症和阿尔茨海默氏症的病人，只能在去世后进行尸检才能最终确诊。

EvestG 一项独特并受专利保护的互联网技术。该技术通过前庭（平衡系统）对神经和脑功能进行灵敏的测量。同行评审的研究文献指出脑前庭电图（EVestG™），有希望对广大神经及精神类疾病进行客观的、准确率超过 85% 的诊断。当该技术经成功推广后，将为全世界的医师提供首个快捷、无痛、低成本并且客观的诊断工具。该诊断不受患者的认知、语种和文化的影响。

类别
设备类

神经科
精神病科

诊断：精神与神经病症

关键技术或领先技术的发展阶段

设计阶段或前期研究阶段

临床前阶段

临床试验中阶段

合作机会
待定

Directory of Australian medtech companies

NeuralDiagnostics

COMPANY DETAILS

Company name: Neural Diagnostics Pty Ltd

Key contact name: Dr Roger Edwards

Job title of key contact: Chief Executive Officer

Company website address: www.neuraldiagnosics.com

Company address: Suite 16, 537 Malvern Road, Toorak VIC 3142

The company is Unlisted.

ABOUT THE COMPANY

Neural Diagnostics Pty Ltd (ND) operates in the multi-billion dollar global annual neuro-technology market servicing the multi-trillion cost burden of disease of mental and neurological conditions.

Neural Diagnostics Pty Ltd (ND) was established in 2005 to develop the EVestG™ System designed to sensitively measure nerve function from brainwaves (neural responses) which indirectly reflect the function of deep brain and brainstem structures, and on analysis by EVestG™ software provide information on brain function. This new technology in the healthcare arena has particular focus on the objective, speedy and economical identification and separation of major Central Nervous Systems (CNS) disorders and monitoring treatment.

Since winning the Australian Broadcasting Corporation “New Inventors” Programs Invention of the Year Award in 2010, the company has successfully achieved Proof of Concept for the technology platform through evaluation in over 400 (active and control group) patients at the Monash Alfred Psychiatry Research Centre (MAPrc) at The Alfred Hospital, Victoria, Australia (supported in part by a \$500,000 Commercialisation Australia Grant) and the Riverview Health Center and University of Manitoba, Winnipeg, Canada. The findings of this research have been published in a Peer-reviewed International Journals.

The company is now ready to take the next steps in its journey of developing technology that facilitates the early, timely and faster identification of complex CNS disorders enabling the right pharmacological and psychological interventions to be prescribed by the treating physicians to deliver a more economic treatment outcome.

With ND’s technology, EVestG™, now successfully patented, with functioning Prototypes in Clinical Settings, and peer-reviewed publications, ND is ready to take the next steps in its journey to being a successful developer of technology that facilitates better diagnosis of patients with CNS disorders.

Neural Diagnostics Pty Ltd product is a potentially, disruptive and transformative breakthrough for the fast and objective measurement of brain function.

KEY OR LEAD TECHNOLOGY

One in four people will suffer from a serious brain disorder such as Autistic Spectrum Disorders, Alzheimer’s, Parkinson’s, Brain Trauma and Injury, depression, bipolar disorder or schizophrenia. Yet, unlike other physical conditions, there is up till now no low-cost, non-invasive, convenient and objective way of measuring brain function that facilitates the fast and accurate diagnosis of emotionally and behaviourally based brain and nervous system disorders. It can take 12 years to diagnose a mental illness such as bipolar disorder and Alzheimer’s can only be definitively diagnosed after death.

EVestG is a unique proprietary internet empowered technology that sensitively measures neural and brain function via a new window into the brain, the Vestibular [balance system]. Published peer-reviewed research indicates Electrovestibulography, EVestG™, promises to be able to objectively

diagnose a broad range of neurological and psychiatric disorders to accuracy greater than 85% on measurement. When successfully commercialised, it will provide the world's clinicians with the first ever quick, painless, low-cost and objective diagnostic tool that is cognitively, linguistically and culturally neutral.

Category

Devices:

Neurology

Psychiatry

Diagnostics: Mental and Neurological Conditions

Other: Theranostic / Companion diagnostic for mental and neurological psychological, pharmacological or physical therapies

Point of development of key or lead technology

Design or early research

Pre-clinical

In clinical trials

OPPORTUNITIES SOUGHT

--